ELIZABETH LAREW: Open Payments
NPI 1427191725 · HARROGATE, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$886 in 50 payments from 19 companies in 2025. Trend: 2023 $995 · 2024 $856 · 2025 $886
Food & beverage: $886
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $171 |
| Sumitomo Pharma America, Inc. | 7 | $112 |
| Lundbeck LLC | 4 | $83 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $82 |
| Novo Nordisk Inc | 4 | $74 |
| PFIZER INC. | 3 | $56 |
| Otsuka America Pharmaceutical, Inc. | 3 | $55 |
| GlaxoSmithKline, LLC. | 3 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $29 |
Products named: REXULTI, GEMTESA, XIFAXAN, VRAYLAR, Ozempic, QULIPTA, TRELEGY ELLIPTA, ELIQUIS.
Industry payments across TN — which companies pay providers there.
